Division of Infection and Global Health, School of Medicine, University of St Andrewsgrid.11914.3c, Scotland, United Kingdom.
Infectious Diseases Research Collaborationgrid.463352.5, Kampala, Uganda.
Microbiol Spectr. 2022 Feb 23;10(1):e0210021. doi: 10.1128/spectrum.02100-21. Epub 2022 Jan 12.
Not all patients produce sputum, yet most available TB tests use sputum. We investigated the utility of a novel RNA-based quantitative test, the tuberculosis molecular bacterial load assay (TB-MBLA), for the detection and quantification of Mycobacterium tuberculosis in stool. Stools from 100 adult individuals were treated with OMNIgene-sputum reagent and tested using Xpert MTB/RIF ultra (Xpert ultra), auramine O smear microscopy (smear), mycobacterial growth indicator tube (MGIT), and Lowenstein-Jensen (LJ) cultures. The remaining portions were frozen at -20°C and later tested by TB-MBLA. MGIT sputum culture was used as a TB confirmatory test and reference for stool tests. Sixty-one of 100 participants were already confirmed TB positive by MGIT sputum culture, 20 (33%) of whom were HIV coinfected. TB-MBLA detected M. tuberculosis in 57/100 stool samples, including 49 already confirmed for TB. The mean bacterial load measured by stool TB-MBLA was 5.67 ± 1.7 log estimated CFU (eCFU) per mL in HIV-coinfected participants, which was higher than the 4.83 ± 1.59 log eCFU per mL among the HIV-negative participants ( = 0.04). The sensitivities (95% confidence intervals [CI]) of stool assays were 80% (68 to 89) and 90% (79 to 98) for TB-MBLA and Xpert ultra, which were both higher than the 44% (32 to 58), 64% (51 to 76), and 62% (45 to 77) for smear, MGIT, and Lowenstein-Jensen (LJ) stool cultures, respectively. The specificity (95% CI) of stool assays was highest for smear, at 97% (87 to 100), followed by Xpert ultra at 91% (76 to 98), TB-MBLA at 79% (63 to 90), LJ at 80% (64 to 91), and MGIT at 62% (45 to 77). Twenty-six percent of MGIT and 21% of LJ stool cultures were indeterminate due to contamination. Detection and quantification of viable M. tuberculosis bacilli in stool raises its utility as an alternative to sputum as a sample type for TB diagnosis. This paper highlights the value of stool as a sample type for diagnosis of tuberculosis. While other studies have used DNA-based assays like the Xpert MTB/RIF and culture to detect Mycobacterium tuberculosis in stool, this is the first study that has applied TB-MBLA, an RNA-based assay, to quantify TB bacteria in stool. The high microbial density and diversity in stool compromises the specificity and sensitivity of culture-based tests due to overgrowth of non-M. tuberculosis flora. Consequently, TB-MBLA becomes the most sensitive and specific test for the detection and quantification of viable TB bacteria in stool. Most crucially, this study raises the possibility of a nonsputum alternative sample type for diagnosis of TB among people who have difficulty in producing sputum.
并非所有患者都能产生痰液,但大多数可用的结核病检测都使用痰液。我们研究了一种新型的基于 RNA 的定量检测方法,即结核分子细菌负荷检测(TB-MBLA),用于检测和定量粪便中的结核分枝杆菌。对 100 名成年个体的粪便进行 OMNIgene-痰试剂处理,并使用 Xpert MTB/RIF ultra(Xpert ultra)、金胺 O 染色显微镜(涂片)、分枝杆菌生长指示管(MGIT)和 Lowenstein-Jensen(LJ)培养物进行检测。其余部分在 -20°C 下冷冻,然后通过 TB-MBLA 进行检测。MGIT 痰培养被用作结核病确认试验和粪便试验的参考。100 名参与者中有 61 名已通过 MGIT 痰培养确认为结核病阳性,其中 20 名(33%)为 HIV 合并感染。TB-MBLA 在 57/100 份粪便样本中检测到结核分枝杆菌,其中 49 份已确认为结核病。MGIT 痰培养证实 HIV 合并感染者粪便中 TB-MBLA 测量的细菌负荷平均值为 5.67±1.7 log 估计 CFU(eCFU)/mL,高于 HIV 阴性参与者的 4.83±1.59 log eCFU/mL(=0.04)。粪便检测的灵敏度(95%置信区间[CI])分别为 80%(68 至 89)和 90%(79 至 98),均高于涂片的 44%(32 至 58)、MGIT 的 64%(51 至 76)和 LJ 的 62%(45 至 77)。粪便检测的特异性(95%CI)最高的是涂片,为 97%(87 至 100),其次是 Xpert ultra,为 91%(76 至 98),TB-MBLA 为 79%(63 至 90),LJ 为 80%(64 至 91),MGIT 为 62%(45 至 77)。由于污染,MGIT 和 LJ 粪便培养物中有 26%和 21%为不确定。粪便中活结核分枝杆菌的检测和定量提高了其作为替代痰液的样本类型用于结核病诊断的实用性。本文强调了粪便作为结核病诊断样本类型的价值。虽然其他研究已经使用 Xpert MTB/RIF 和培养等基于 DNA 的检测方法来检测粪便中的结核分枝杆菌,但这是第一项应用 TB-MBLA(一种基于 RNA 的检测方法)来定量粪便中结核细菌的研究。粪便中微生物密度和多样性高,由于非结核分枝杆菌菌群的过度生长,导致基于培养的检测的特异性和灵敏度降低。因此,TB-MBLA 成为检测和定量粪便中活结核分枝杆菌最敏感和最特异的检测方法。最重要的是,这项研究提出了一种非痰液替代样本类型,用于诊断那些难以产生痰液的人群中的结核病。